Summary

for people ages 18 years and up (full criteria)
at Orange, California and other locations
study started
estimated completion

Description

Summary

This Phase I/II open-label, randomized, dose-escalation study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VAL-1221 versus Myozyme®/Lumizyme® in participants with late-onset glycogen storage disease-II (GSD-II) (Pompe disease)

Official Title

A Three-Month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Versus Myozyme®/Lumizyme® in Patients With Late-Onset GSD-II (Pompe Disease) Followed by Open-Label Treatment With VAL-1221 in All Patients

Details

The study will be conducted in two parts. Part 1 is a 3-month active control phase which comprises 3 sequential cohorts of 4 participants each randomized to treatment with either VAL-1221 (at 3, 10, or 30 milligrams/kilogram [mg/kg]) or positive control (recombinant human acid alpha-glucosidase [rhGAA]). Eligible participants who complete Part 1, including those maintained on rhGAA, will be offered inclusion in Part 2 of the study. Part 2 is a 9-month uncontrolled extension to evaluate long-term effects of VAL-1221 given by intravenous (IV) infusion once every other week at doses up to 30 mg/kg.

Keywords

Pompe DiseaseGSD-IIGlycogen Storage DiseasesGAAGlycogen Storage Disease Type IIVAL-1221RhGAAVAL-1221 3 mg/kgVAL-1221 10 mg/kgVAL-1221 30 mg/kg

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participant is able and willing to provide informed consent prior to any study procedures are performed
  • Diagnosis of GSDII based on one of the following:
  • Endogenous cultured skin fibroblast GAA activity less than (<) 40 percent (%) of adult normal level
  • Endogenous whole blood or dried blood spot GAA activity in deficiency range
  • Genetic analysis showing pathogenic variants in both alleles
  • Onset of Pompe disease-related symptoms after 1 year of age
  • Previously treated with Myozyme or Lumizyme for at least 12 months and on a stable regimen for the past 6 months
  • Sexually active participants who are willing to use an acceptable method of contraception (abstinence, oral contraceptives, barrier method with spermicide, surgical sterilization, implanted or injectable contraceptives with a stable dose for at least 1 month prior to Baseline, hormonal intra-uterine device [IUD] inserted at least 1 month prior to Baseline) during the study and for 30 days after completion of treatment
  • If participant is female and not considered to be of childbearing potential, she is at least 2 years post-menopause, has undergone a tubal ligation, a total hysterectomy or bilateral oophorectomy
  • If participant is female and of childbearing potential, she has a negative serum pregnancy test during screening and Baseline and must be willing to undergo pregnancy testing at specific intervals during the study
  • Participant meets at least one of the following criteria: greater than (>) 30% and <80% predicted upright forced volume capacity (FVC) or participant is able to walk >20% but <80% predicted normal on 6-minute walk test with or without use of assistive devices
  • Able to comply with protocol requirements

You CAN'T join if...

  • Cardiac involvement in first year of life
  • Anti-GAA antibody titers >1:51,200 at two time points
  • Prior use of chaperone therapy for GSD-II within the last 12 months
  • Use of immunosuppressive medication other than glucocorticoids within 6 months prior to study enrollment
  • Use of invasive ventilatory assistance other than Bilevel Positive Airway Pressure (BiPAP) at night or during periods of rest
  • Has received any investigational medication or has enrolled in any study involving investigational drugs or therapies within 30 days prior to first dose of study drug
  • Start of or change in usual regimen of albuterol or respiratory muscle training within 30 days prior to first dose of study drug
  • History of sensitivity to any of the constituents of the study drug
  • Participant is breastfeeding or planning to become pregnant or to breastfeed during the study or is currently breastfeeding
  • Participant has a medical condition or circumstance that, in the opinion of the investigator, might compromise the participant's ability to comply with the protocol or the participant's well-being or safety
  • Participant has any condition that, in the view of the investigator, places the participant at high risk of poor treatment compliance or of not completing the study

Locations

  • University of California, Irvine
    OrangeCalifornia92868United States
  • Duke University Medical Center
    DurhamNorth Carolina27710United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Valerion Therapeutics, LLC
ID
NCT02898753
Phase
Phase 1/2
Study Type
Interventional
Last Updated